| Title | PET Imaging of Neovascularization with Ga-68-3PRGD(2) for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy |
| Authors | Shi, Jiyun Jin, Zhongxia Liu, Xujie Fan, Di Sun, Yi Zhao, Huiyun Zhu, Zhaohui Liu, Zhaofei Jia, Bing Wang, Fan |
| Affiliation | Peking Univ, Med Isotopes Res Ctr, Beijing 100191, Peoples R China. Chinese Acad Sci, Inst Biophys, Interdisciplinary Lab, Beijing 100101, Peoples R China. Peking Univ, Dept Radiat Med, Beijing 100191, Peoples R China. Beijing Union Med Coll Hosp, Dept Nucl Med, Beijing 100857, Peoples R China. Peking Univ, Med & Hlth Analyt Ctr, Beijing 100191, Peoples R China. |
| Keywords | antiangiogenic therapy in vivo monitoring molecular imaging radiotracer endostar POSITRON-EMISSION-TOMOGRAPHY RECOMBINANT HUMAN ENDOSTATIN ADVANCED SOLID TUMORS INTEGRIN ALPHA(V)BETA(3) LUNG-CANCER TARGETED THERAPIES ENDOTHELIAL-CELLS BREAST-TUMOR ANGIOGENESIS EXPRESSION |
| Issue Date | 2014 |
| Publisher | molecular pharmaceutics |
| Citation | MOLECULAR PHARMACEUTICS.2014,11,(11),3915-3922. |
| Abstract | Antiangiogenic therapy is an effective strategy to inhibit tumor growth. Endostar, as an approved antiangiogenesis agent, inhibits the newborn vascular endothelial cells, causing the decrease of integrin alpha beta(3) expression. Radiolabeled 3PRGD(2), a novel PEGlayted RGD dimer probe (PEG(4)-E[PEG(4)-c(RGDfK)](2)) showed highly specific targeting capability to integrin alpha beta(3), which could be used for monitoring the efficacy of Endostar antiangiogenic therapy. In this study, Ga-68-3PRGD(2) PET imaging was performed in Endostar treated/untreated Lewis Lung Carcinoma (LLC) mice on days 3, 7, 14, and 21 post-treatment for monitoring the tumor response to Endostar treatment, with the F-18-FDG imaging as control. As a result, Ga-68-3PRGD2 PET reflected the tumor response to Endostar antiangiogenic therapy much earlier (day 3 post-treatment vs day 14 post-treatment) and more accurately than that of F-18-FDG metabolic imaging, which provides new opportunities to develop individualized therapeutic approaches, establish optimized dosages and dose intervals for effective treatment that improve the survival rate of patients. |
| URI | http://hdl.handle.net/20.500.11897/342264 |
| ISSN | 1543-8384 |
| DOI | 10.1021/mp5003202 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 医学部待认领 |
